Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Pharmathen S.A., 6, Dervenakion str., 153 51 Pallini, Attiki, Greece
Risedronate sodium 35 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White round biconvex film-coated tablet with diameter of 11.2 mm, 5.0 mm in thickness and embossed with “35” on one side. |
Each film-coated tablet contains 35 mg risedronate sodium which is equivalent to 32.5 mg risedronic acid.
Excipients with known effect:
Each film-coated tablet contains 1.9 mg lactose.
Each film-coated tablet contains 0.115 mmol (2.64 mg) of sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Risedronic acid |
Risedronic acid is a pyridinyl bisphosphonate that binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption. The bone turnover is reduced while the osteoblast activity and bone mineralisation is preserved. |
| List of Excipients |
|---|
|
Tablet core: Starch, pregelatinised (maize) Film coating: Hypromellose |
Nature of container: Opaque PVC/PE/PVDC/Aluminium blister in a carton box.
Pack sizes: 1, 2, 4, 10, 12, 16, 24 film-coated tablets
Not all pack sizes may be marketed.
Pharmathen S.A., 6, Dervenakion str., 153 51 Pallini, Attiki, Greece
PL 17277/0239
11/06/2014
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
